

Jonathan W. Fountain  
Nevada Bar No. 10351  
JFountain@LRLaw.com  
LEWIS AND ROCA LLP  
3993 Howard Hughes Parkway  
Suite 600  
Las Vegas, NV 89169  
Phone: (702) 949-8340  
Fax: (702) 949-8374

Of counsel:

Adam K. Mortara  
(Will comply with LR IA 10-2 within 45 days)  
adam.mortara@bartlit-beck.com  
Matthew R. Ford  
(Will comply with LR IA 10-2 within 45 days)  
matthew.ford@bartlit-beck.com  
BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP  
54 W. Hubbard Street, Suite 300  
Chicago, IL 60654  
Phone: (312) 494-4400  
Fax: (312) 494-4440

Attorneys for Plaintiff  
BAYER PHARMA AG

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEVADA**

BAYER PHARMA AG

Plaintiff,

vs.

WARNER CHILCOTT COMPANY, LLC  
and WARNER CHILCOTT (US), LLC

Defendants.

**COMPLAINT  
(JURY DEMAND)**

Plaintiff Bayer Pharma AG (“Bayer”) brings this Complaint for patent infringement against Defendants Warner Chilcott Company, LLC and Warner Chilcott (US), LLC (collectively “Warner Chilcott”) and alleges the following:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of the United States, including 35 U.S.C. §§ 271, 281-285.



1 sales of Loestrin 24 FE. Warner Chilcott (US), LLC has thus purposefully availed itself of the  
2 benefits and protections of Nevada's laws such that it should reasonably anticipate being sued in  
3 this jurisdiction. Warner Chilcott Company, LLC is subject to personal jurisdiction in Nevada  
4 because Warner Chilcott Company, LLC manufactures pharmaceutical drugs with the knowledge  
5 and intent that Warner Chilcott Company, LLC's drugs will be sold in the United States, including  
6 within Nevada, by Warner Chilcott (US), LLC. Warner Chilcott Company, LLC has thus engaged  
7 in systematic and continuous business contacts within Nevada, and has therefore purposefully  
8 availed itself of the benefits and protections of Nevada's laws such that it should reasonably  
9 anticipate being sued in this jurisdiction.

10 9. Venue is proper in the District of Nevada pursuant to 28 U.S.C. §§ 1391, 1400(b)

11 **FACTUAL BACKGROUND**

12 10. Plaintiff Bayer Pharma AG is the assignee of the '916 Patent.

13 11. Without limitation, the '916 Patent claims a method of inducing contraception in a  
14 female of reproductive age by administering a monophasic composition comprising 15 µg to 20  
15 µg of ethinylestradiol and a contraceptively effective amount of a gestagen wherein the  
16 composition is administered for 23 or 24 days followed by 5 or 4 pill-free or non-hormonal pill  
17 days.

18 12. Defendant Warner Chilcott sells Loestrin 24 FE tablets in the United States as a 28-  
19 day oral contraceptive regimen. Loestrin 24 FE's regimen contains 24 tablets comprising a  
20 contraceptively effective amount of norethindrone acetate and 20 µg ethinyl estradiol; and 4 non-  
21 hormonal placebo tablets.

22  
23 **COUNT I - INFRINGEMENT**  
**OF UNITED STATES REISSUE PATENT NO. 43,916**

24 13. Bayer restates and realleges each of the assertions set forth in Paragraphs 1 through  
25 12.

26 14. The administration of the oral contraceptive Loestrin 24 FE infringes one or more  
27 claims of the '916 Patent under 35 U.S.C. § 271 either literally or under the doctrine of  
28 equivalents.

15. Defendant Warner Chilcott has knowledge of the '916 Patent. By letter dated February 18, 2013, Bayer informed Warner Chilcott that that it induced infringement of the '916 Patent through sales of Loestrin 24 FE. Warner Chilcott also has knowledge of the '916 Patent based on the filing of this lawsuit.

16. On information and belief, Warner Chilcott has knowledge that its sales of Loestrin 24 FE will result in the infringement of the '916 Patent. On information and belief, Warner Chilcott is aware or should be aware of the widespread prescription of Loestrin 24 FE by doctors or other healthcare practitioners. The label for Loestrin 24 FE instructs doctors or other healthcare practitioners as well as patients to administer Loestrin 24 FE with a regimen of 24 tablets containing 20 µg of estrogen and a contraceptively effective amount of a gestagen; followed by 4 pill-free or sugar pill days.

17. On information and belief, Warner Chilcott has the specific intent to encourage infringement by others of the '916 Patent based on its distribution of Loestrin 24 FE for purposes of its administration as an oral contraceptive.

WHEREFORE, Bayer is entitled to recover from Warner Chilcott the damages sustained by Bayer as a result of Warner Chilcott's wrongful acts in an amount subject to proof at trial, including an amount not less than a reasonable royalty together with interest and costs as fixed by this Court under 35 U.S.C. § 284.

#### **JURY DEMAND**

Bayer hereby demands a trial by jury on all issues so triable.

Dated: this 19th day of February, 2013.

Respectfully submitted,

LEWIS AND ROCA LLP

By: /s/ Jonathan W. Fountain

Jonathan W. Fountain  
Nevada Bar No. 10351  
JFountain@LRLaw.com  
3993 Howard Hughes Parkway  
Suite 600  
Las Vegas, NV 89169  
Phone: (702) 949-8340

Fax: (702) 949-8374

Of counsel:

BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP

Adam K. Mortara

(Will comply with LR IA 10-2 within 45 days)

adam.mortara@bartlit-beck.com

Matthew R. Ford

(Will comply with LR IA 10-2 within 45 days)

matthew.ford@bartlit-beck.com

54 W. Hubbard Street, Suite 300

Chicago, IL 60654

Phone: (312) 494-4400

Fax: (312) 494-4440

Attorneys for Plaintiff

BAYER PHARMA AG